Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials
Akinkuolie AO, Ngwa JS, Meigs JB, Djoussé L
Clinical nutrition (Edinburgh, Scotland) · 121 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- NHLBI NIH HHS
- Subvenciones
- National Heart, Lung, and Blood Institute (N01-HC-025195)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2011-09-30 · Clin Nutr · vol. 30 · número 6 · págs. 702–707
- Editorial
- Elsevier BV
- Citado
- 166 citas · más que el 85% de estudios similares · 1.9× el promedio de su campo
- Referencias
- 60 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Fatty Acid Research and Health · Diet, Metabolism, and Disease · Nutritional Studies and Diet
- Palabras clave
- omega-3 polyunsaturated fatty acids, insulin sensitivity, glucose metabolism, metabolic syndrome, type 2 diabetes, QUICKI, HOMA-IR, dietary supplementation
- MeSH
- humans, insulin resistance, glucose, fatty acids, omega-3, randomized controlled trials as topic, metabolic syndrome
4 autores
- Akintunde O. Akinkuolie🇺🇸Boston University
- Julius Suh Ngwa🇺🇸Boston University
- James B. Meigs🇺🇸Harvard University
- Luc Djoussé🇺🇸Brigham and Women's Hospital; Harvard University; VA Boston Healthcare System
Resumen
El texto original del estudio, en el idioma en que se publicó.
Unlabelled
BACKGROUND &AIM: n-3 PUFA has been shown to decrease the risk of several components of the metabolic syndrome; however, the role of n-3 PUFA on glucose metabolism is not clear. Our aim was to systematically review the effect of n-3 PUFA on IS by conducting a meta-analysis of available RCTs.
Methods
We followed the guidelines of Cochrane's review of systematic interventions. We searched MEDLINE, EMBASE, CENTRAL and clinicaltrials.gov from the beginning of each database until October 2010. Meta-analysis was performed using a random effects model to estimate a pooled SMD and the corresponding 95% CI.
Results
From 303 screened citations, 11 RCTs (n = 618) were eligible for inclusion in the analysis. In a pooled estimate, n-3 PUFA intervention had no effects on IS compared to placebo (SMD 0.08, 95% CI -0.11-0.28). Similarly, n-3 PUFA had no effects on IS in sub-group analyses (Type 2 diabetes vs. other population; QUICKI and other test subgroups). In the HOMA subgroup, n-3 PUFA was associated with a statistically significant increase in IS (SMD 0.30, CI 0.03-0.58) when compared to placebo.
Conclusion
This meta-analysis is consistent with a lack of n-3 PUFA effects on IS.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.